Bladder cancer and apoptosis: matters of life and death

Lancet Oncology

Volumn 8, Issue 2, 2007, Pages 91-92

  Real, Francisco X ^a   Malats, Núria ^b  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYTOCHROME C; PROTEIN BCL 2; PROTEIN P53; SURVIVIN;

ACCURACY; APOPTOSIS; BLADDER CANCER; CANCER CLASSIFICATION; CANCER GROWTH; CELL FUNCTION; CYSTECTOMY; DISEASE MARKER; GENE ACTIVATION; HOMEOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MEDICAL SOCIETY; MEDICAL SPECIALIST; MITOCHONDRION; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WORLD HEALTH ORGANIZATION;

APOPTOSIS; CASPASE 3; CYSTECTOMY; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 33846552317     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70008-6     Document Type: Letter

References (11)

1. Larsson P., Wijkstrom H., Thorstenson A., et al. A population-based study of 538 patients with newly detected urinary baldder neoplasms followed during 5 years. Scand J Urol Nephrol 37 (2003) 195-201
2. Karam J., Lotan Y., Karakiewicz P., et al. The utility of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8 (2007) 128-136
3. Hanahan D., and Weinberg R. The hallmarks of cancer. Cell 100 (2000) 57-70
4. Strasser A., Harris A., Bath M., and Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348 (1990) 331-333
5. Fulda S., and Debatin K. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25 (2006) 4798-4811
6. In: Eble J., Sauter G., Epstein J., and Sesterhenn I. (Eds). World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs (2004), IARC Press, Lyon
7. Habuchi T., Marberger M., Droller M., et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 66 suppl 1 (2005) 64-74
8. Malats N., Bustos A., Nascimento C., et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6 (2005) 678-686
9. McShane L., Altman D., Sauerbrei W., et al., for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97 (2005) 1180-1184
10. Knowles M. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 27 (2006) 361-373
11. Orntoft T., Zieger K., and Dyrskjot L. Recent developments in molecular profiling of bladder cancer. Curr Opin Urol 16 (2006) 377-381